Browse the corpus

Atracurium is a non-depolarizing neuromuscular blocking agent that facilitates endotracheal intubation and skeletal muscle relaxation during surgery or mechanical ventilation. This activity reviews the indications, mechanism of action, and contraindications of atracurium, emphasizing its role in perioperative and critical care settings. Competitive inhibition of acetylcholine at nicotinic receptors underlies the pharmacologic effect, necessitating precise dosing and vigilant monitoring to optimize neuromuscular blockade while minimizing adverse effects. Key considerations include dosing strategies, drug interactions, and adverse event management, with a focus on histamine release and potential cardiovascular effects. Discussing toxicity, metabolism, and elimination pathways highlights patient-specific factors influencing drug selection. The role of the interprofessional healthcare team in administering and monitoring atracurium ensures safe and effective use in clinical practice. This activity enhances understanding of atracurium’s pharmacologic profile, supporting informed decision-making in anesthesia and critical care management. Objectives: Identify the FDA-approved indications and off-label uses of atracurium. Screen patients for potential contraindications of atracurium administration. Determine the appropriate monitoring of patients receiving atracurium therapy. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from atracurium therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose In cases involving atracurium overdose, pharmacological effects are enhanced. Histamine release and cardiovascular effects, such as hypotension, may occur. In pediatric patients, unintentional doses up to 1 mg/kg (5 to 6 times the ED95) lead to delayed recovery (50 to 55 minutes), with minimal cardiovascular changes. In adults, a dose of 1.3 mg/kg results in a prolonged recovery time (83 minutes) and moderate hemodynamic effects, including increased mean arterial pressure and heart rate (13% and 27%, respectively), which persist for about 40 minutes but do not require specific intervention. Management of Overdose The primary focus in managing an atracurium overdose is ensuring proper airway and ventilation. Emergency medicine physicians maintain manual or mechanical ventilation when necessary. Peripheral nerve stimulation is used to monitor neuromuscular block recovery. Recovery can be enhanced with anticholinesterase agents like neostigmine, edrophonium, or pyridostigmine combined with anticholinergic drugs such as atropine or glycopyrrolate. If cardiovascular support is needed, fluids and vasopressors should be administered. Critical care physicians should closely monitor the patient's hemodynamic status and respiratory function. Due to the potential for prolonged recovery, intensive care support is provided until the patient stabilizes and fully recovers from the neuromuscular block. Lethal self-administration in healthcare providers remains a concern.[36]

Atracurium is a neuromuscular blocking agent commonly used in anesthesia. This medication is known to cause histamine release, which can lead to various adverse drug reactions. Anesthesiologists must determine the appropriate use and dosage of atracurium and communicate their plan to nurse anesthetists (CRNAs). Surgeons should ensure that the timing of atracurium administration aligns with the surgical procedure and maintain communication with the anesthesia team. Pharmacists can verify potential drug interactions and recommend dosage adjustments as needed. Nurses are responsible for monitoring the patient's condition and alerting the CRNA to complications. Nurses and residents should closely monitor patients in the medical intensive care unit (MICU), surgical intensive care unit (SICU), and post-anesthesia care unit (PACU). A large retrospective cohort study reveals significant provider variability in the use of neuromuscular blocking agents (NMBAs) during general anesthesia, with nurse anesthetists (CRNAs) adapting their practice more precisely to the preferences of individual surgeons. This highlights the importance of developing standardized guidelines to optimize NMBA use, improve patient safety, and enhance clinical outcomes through better interprofessional collaboration.[37] An evidence-based approach is essential to optimize treatment outcomes and minimize adverse effects. Effective interprofessional communication and coordination are crucial for excellent care from induction to recovery. An interprofessional team approach involving clinicians, pharmacists, and nurses is vital for reducing potential adverse effects and improving patient outcomes related to atracurium.